• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Smith Robin L

    9/13/21 6:17:47 PM ET
    $GXGX
    Business Services
    Finance
    Get the next $GXGX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Smith Robin L

    (Last) (First) (Middle)
    C/O CELULARITY INC.
    170 PARK AVENUE

    (Street)
    FLORHAM PARK NJ 07932

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Celularity Inc [ CELU ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/09/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $6.72 09/09/2021 A 56,053 (1) 09/09/2031 Class A Common Stock 56,053 $0.00 56,053 D
    Explanation of Responses:
    1. This option shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, September 9, 2021, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through each such date.
    /s/ Keary Dunn, Attorney-in-Fact 09/13/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GXGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GXGX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GXGX
    SEC Filings

    View All

    SEC Form S-8 filed by GX Acquisition Corp.

    S-8 - Celularity Inc (0001752828) (Filer)

    10/4/21 5:05:24 PM ET
    $GXGX
    Business Services
    Finance

    SEC Form 424B3 filed by GX Acquisition Corp.

    424B3 - Celularity Inc (0001752828) (Filer)

    9/17/21 8:37:37 AM ET
    $GXGX
    Business Services
    Finance

    SEC Form 8-K filed by GX Acquisition Corp.

    8-K - Celularity Inc (0001752828) (Filer)

    9/15/21 4:49:33 PM ET
    $GXGX
    Business Services
    Finance

    $GXGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal

    NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ:GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amendment to GX's amended and restated certificate of incorporation to extend the date by which GX must effectuate its initial business combination  from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021, GX entered into a Merger Agreement and Plan of Reorganization (the "Merger Agreement") with Celularity Inc. ("Celularity"), Alpha First Merger Sub, Inc. and Alpha Second Merger Sub, LLC. Upon the terms and subject to the conditions of the Merger Agreement, Celularity wi

    5/14/21 4:45:00 PM ET
    $GXGX
    Business Services
    Finance

    GX Acquisition Corp. Announces Additional Contributions to Trust Account

    NEW YORK, May 10, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ:GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend GX's amended and restated certificate of incorporation to extend the date by which GX must complete its initial business combination from May 23, 2021 to July 31, 2021 (the "Extension" and such later date, the "Extended Date"). This proposal will be voted on by stockholders at the upcoming special meeting of stockholders on May 14, 2021. The Extension will allow GX until the Extended Date to complete its initial business combination. In order to support this proposal, GX has agreed that, if the

    5/10/21 7:30:00 AM ET
    $GXGX
    Business Services
    Finance

    Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

    Celularity to leverage Palantir's next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity Investment, combined with previously announced PIPE investment, brings over$100 million in new funding to Celularity FLORHAM PARK, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. ("Celularity"), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and Palantir Technologies Inc. (NYSE:PLTR), a software company t

    5/5/21 8:00:00 AM ET
    $PLTR
    $GXGX
    Computer Software: Prepackaged Software
    Technology
    Business Services
    Finance

    $GXGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on GX Acquisition Corp with a new price target

    BTIG Research initiated coverage of GX Acquisition Corp with a rating of Buy and set a new price target of $16.00

    3/26/21 7:12:09 AM ET
    $GXGX
    Business Services
    Finance

    $GXGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pecora Andrew L

    4 - Celularity Inc (0001752828) (Issuer)

    9/17/21 2:48:53 PM ET
    $GXGX
    Business Services
    Finance

    SEC Form 3 filed by new insider Pecora Andrew L

    3 - Celularity Inc (0001752828) (Issuer)

    9/17/21 2:44:19 PM ET
    $GXGX
    Business Services
    Finance

    SEC Form 4 filed by Mirakhur Beloo

    4 - Celularity Inc (0001752828) (Issuer)

    9/15/21 6:50:54 PM ET
    $GXGX
    Business Services
    Finance

    $GXGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GX Acquisition Corp.

    SC 13G - Celularity Inc (0001752828) (Subject)

    7/26/21 5:19:50 PM ET
    $GXGX
    Business Services
    Finance

    SEC Form SC 13D filed by GX Acquisition Corp.

    SC 13D - Celularity Inc (0001752828) (Subject)

    7/26/21 5:16:55 PM ET
    $GXGX
    Business Services
    Finance

    SEC Form SC 13G filed by GX Acquisition Corp.

    SC 13G - Celularity Inc (0001752828) (Subject)

    7/26/21 5:10:46 PM ET
    $GXGX
    Business Services
    Finance